Joseph Mikhael, MD, MEd, FRCPC

Future Therapies in Multiple Myeloma

Joseph Mikhael , MD, MEd, FRCPC;

08/29/2020

Debate: Smoldering Myeloma: Not To Treat

Joseph Mikhael , MD, MEd, FRCPC;

03/09/2020

The Treatment of Smoldering Myeloma – Only Few Should Receive Treatment

Joseph Mikhael , MD, MEd, FRCPC;

10/24/2019

Genomics 102: Clinical use for treatment individualization – including double hit myeloma

Joseph Mikhael , MD, MEd, FRCPC;

10/19/2018

Depth of Response of Isatuximab (Isa) plus Carfilzomib (K) and Dexamethasone (d) in Relapsed Multiple Myeloma: IKEMA Updated Analysis

Introduction:Achievement of minimal residual disease negativity (MRD‚Äì) status in multiple myeloma (MM) is associated with improved progression-free survival (PFS) and overall survival. ...

Nelson Castro ;

Tomas Pika ;

Javier De la Rubia ;

Angelo Maiolino ;

Anthony Reiman ;

Thomas G. Martin III, MD;

Sylvia Marion ;

Joseph Mikhael , MD, MEd, FRCPC;

Roman Hajek ;

Sosana Delimpasi ;

Joaquin Martinez-Lopez ;

Sandrine Mace ;

Phillippe Moreau ;

Kwee Yong ;

Meletios-Athanasios Dimopoulos ;

France Casca ;

Marie-Laure Risse ;

Bradle Augustson ;

11/04/2022

Updated Progression-free Survival (PFS) and Depth of Response in IKEMA, A Randomized Phase 3 Trial of Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) vs Kd in Relapsed Multiple Myeloma (MM)

Introduction:The anti-CD38 antibody Isa in combination with Kd is approved in various countries for patients (pts) with relapsed MM after ‚â•1 prior therapy, based on primary interim anal...

Thomas G. Martin III, MD;

Joseph Mikhael , MD, MEd, FRCPC;

Roman Hajek ;

Sandrine Mace ;

Phillippe Moreau ;

Kwee Yong ;

Marcelo Capra ;

Thierry Facon ;

France Casca ;

Marie-Laure Risse ;

Meletios-Athanasios Dimopoulos ;

11/04/2022

Joseph Mikhael, MD, City of Hope Cancer Center

Conference Coverage

Strategies for Treating Patients With Multiply Relapsed Multiple Myeloma

01/19/2024

Joseph Mikhael , MD, MEd, FRCPC;

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment regimens like CELMoDs and XP01 inhibitors for patients with multiply relapsed multiple myeloma.

At the 2023 Lymphoma, Leukemia &...

01/19/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Benefits of MRD Testing for the Treatment of Patients With Multiple Myeloma

01/19/2024

Joseph Mikhael , MD, MEd, FRCPC;

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, participated in a debate on the benefits of minimal residual disease testing in multiple myeloma treatment.

At the 2023 Lymphoma, Leukemia &...

01/19/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Treatment Options for When Immune Therapies Fail Among Patients With R/R MM

10/24/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment possibilities for patients with  R/R multiple myeloma when immune therapies, such as antibody drug conjugates, CAR T-cell therapy, and bispecific...

At the 2024 Lymphoma, Leukemia &...

10/24/2024

Lymphoma, Leukemia & Myeloma Network